Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan
Status:
Completed
Trial end date:
2018-09-13
Target enrollment:
Participant gender:
Summary
This study aims to determine if the addition of Canagliflozin (Invokana™) therapy to
monotherapy of metformin is more effective at achieving the double composite endpoint of a
reduction in HbA1c (≥ 0.3%) and weight loss (≥1kg) 3-4 weeks post-Ramadan. The study will
also include patients currently on dual therapy, specifically metformin plus a sulphonylurea,
pioglitazone or repaglinide to determine whether switching to metformin plus Canagliflozin
(Invokana™) is more effective at achieving the composite endpoint compared to those remaining
on previous dual therapy. There are a number of secondary outcomes including weight loss,
rates of hypoglycaemia, blood pressure and a number of biochemical endpoints.